Ro24-7429 is a potent and orally active HIV-1 transactivator protein Tat antagonist. Ro24-7429 is also a runt-related transcription factor 1 (RUNX1) inhibitor. Ro24-7429 has anti-HIV, antifibrotic and anti-inflammatory effects In Vitro Ro 24-7429 (0.1-5 μM; 3 days) induces apoptosis of cultured PBMCs in a dose-dependent manner. ?\nRo 24-7429 (1-25 μM) also induces apoptosis and inhibits antigen-induced lymphocyte proliferation. ?\nRo24-7429 (50-200 μM; 24-72 hours) strongly inhibits the proliferation of A549 and HLF cells in a dose-dependent manner. Ro24-7429 treatment (75 μM) significantly reduces TNF-α-induced up-regulation of RUNX1 mRNA by 50% at 48 hours. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Apoptosis AnalysisCell Line: Peripheral blood mononuclear cells (PBMCs) Concentration: 0.1 μM, 1 μM, 5 μM Incubation Time: 3 days Result: Induced a dose-dependent increase in apoptosis of cultured PBMCs. In Vivo Ro24-7429 (17.5-70 mg/kg; i.p.; daily; for 14 or 21 days) treatment robustly ameliorates lung fibrosis and inflammation in the Bleomycin-induced pulmonary fibrosis (PF) mouse model. Ro24-7429 curbs expression of fibrosis markers in injured mouse lungs. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6J male and female mice (aged 6 to 8 weeks) induced by BleomycinDosage: 17.5 mg/kg, 35 mg/kg, and 70 mg/kg Administration: i.p.; daily; for 14 or 21 days Result: Ameliorated lung fibrosis and inflammation in the Bleomycin-induced PF mouse model. Form:Solid IC50& Target:HIV-1